SCHEMBL147260

SCHEMBL147260

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4ccccc4)cc32)c(C)c1CCC(=O)O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 13/20 0.76
KDR P35968 13/20 0.76
PDGFRB P09619 12/20 0.76
EGFR P00533 5/20 0.76
AURKA O14965 6/20 0.69
RET P07949 2/20 0.69
FLT1 P17948 2/20 0.69
FLT3 P36888 2/20 0.69
MAP4K2 Q12851 2/20 0.69
STK3 Q13188 2/20 0.69
AURKB Q96GD4 2/20 0.69
GAK O14976 1/20 0.69
RPS6KA5 O75582 1/20 0.69
RPS6KA4 O75676 1/20 0.69
LATS1 O95835 1/20 0.69
CSNK2A2 P19784 1/20 0.69
MAP2K2 P36507 1/20 0.69
ZAP70 P43403 1/20 0.69
MAP2K1 Q02750 1/20 0.69
STK4 Q13043 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144133 0.91 KDR (0.63) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL6326012 0.90 AURKA (0.68) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL145151 0.89 FGFR1 (0.73) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL6331049 0.88 AURKA (0.66) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL6335062 0.87 AURKA (0.64) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL143571 0.86 ALK (0.63) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL6331096 0.86 AURKA (0.62) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL144608 0.85 AURKA (0.63) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL144702 0.84 PDGFRB (0.76) FGFR1KDRPDGFRBEGFRAURKA
SCHEMBL142474 0.82 MET (0.55) FGFR1KDRPDGFRBEGFRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 FGFR1 5/4885KDR 1077/4885PDGFRB 467/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 FGFR1 5/4885KDR 1077/4885PDGFRB 467/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 FGFR1 637/4885KDR 398/4885PDGFRB 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.